XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2

REVENUES (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Contract with Customer, Contract Asset

The following table summarizes our contract assets:

(in millions)			June 30, 2021			December 31, 2020
Contract manufacturing services			$	72		$	47
Software sales			39			40
Bundled equipment and consumable medical products contracts			50			47
Contract assets			$	161		$	134

The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:

(in millions)			June 30, 2021			December 31, 2020
Prepaid expenses and other current assets			$	98		$	70
Other non-current assets			63			64
Contract assets			$	161		$	134
Accrued expenses and other current liabilities			$	43		$	32
Other non-current liabilities			44			34
Contract liabilities			$	87		$	66

Net Sales from Contracts with Customers by Global Business Unit

The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:

			Three Months Ended June 30,
			2021									2020
(in millions)			U.S.			International			Total			U.S.			International			Total
Renal Care 1			$	217		$	747		$	964		$	209		$	710		$	919
Medication Delivery 2			444			253			697			394			211			605
Pharmaceuticals 3			162			384			546			208			273			481
Clinical Nutrition 4			84			153			237			75			141			216
Advanced Surgery 5			144			112			256			94			74			168
Acute Therapies 6			61			127			188			72			114			186
BioPharma Solutions 7			65			118			183			54			62			116
Other 8			21			6			27			21			6			27
Total Baxter			$	1,198		$	1,900		$	3,098		$	1,127		$	1,591		$	2,718

			Six Months Ended June 30,
			2021									2020
(in millions)			U.S.			International			Total			U.S.			International			Total
Renal Care 1			$	433		$	1,453		$	1,886		$	413		$	1,376		$	1,789
Medication Delivery 2			855			494			1,349			843			440			1,283
Pharmaceuticals 3			362			736			1,098			428			569			997
Clinical Nutrition 4			167			304			471			154			279			433
Advanced Surgery 5			270			203			473			231			161			392
Acute Therapies 6			142			253			395			132			210			342
BioPharma Solutions 7			109			209			318			102			128			230
Other 8			40			14			54			41			13			54
Total Baxter			$	2,378		$	3,666		$	6,044		$	2,344		$	3,176		$	5,520

1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.

3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

7BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies.

8Other includes sales of miscellaneous product and service offerings.

Sales-type Lease, Lease Income

The components of lease revenue for the three and six months ended June 30, 2021 were:

(in millions)			Three months ended June 30, 2021			Six months ended June 30, 2021
Sales-type lease revenue			$	10		$	16
Operating lease revenue			35			69
Variable lease revenue			15			32
Total lease revenue			$	60		$	117

The components of lease revenue for the three and six months ended June 30, 2020 were:

(in millions)			Three months ended June 30, 2020			Six months ended June 30, 2020
Sales-type lease revenue			$	10		$	16
Operating lease revenue			14			28
Variable lease revenue			20			38
Total lease revenue			$	44		$	82

Operating Lease, Lease Income

The components of lease revenue for the three and six months ended June 30, 2021 were:

(in millions)			Three months ended June 30, 2021			Six months ended June 30, 2021
Sales-type lease revenue			$	10		$	16
Operating lease revenue			35			69
Variable lease revenue			15			32
Total lease revenue			$	60		$	117

The components of lease revenue for the three and six months ended June 30, 2020 were:

(in millions)			Three months ended June 30, 2020			Six months ended June 30, 2020
Sales-type lease revenue			$	10		$	16
Operating lease revenue			14			28
Variable lease revenue			20			38
Total lease revenue			$	44		$	82

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981

+ Details

Name:	us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981

+ Details

Name:	us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration